COMMUNIQUÉS West-GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/06/2026
SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common [...]
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/06/2026
WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States
17/06/2026
CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced its entry into the global [...]
Premier Health of America Provides Update on Management Cease Trade Order
17/06/2026
MONTREAL, June 17, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health” , or the “Company” ) is providing this bi-weekly default status report in accordance with National Policy 12-203 [...]
RESTEM to Present at BIO International Convention
17/06/2026
MIAMI, June 17, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that CEO, [...]
Compte-rendu de l’assemblée générale de TME Pharma
17/06/2026
Compte-rendu de l’assemblée générale de TME Pharma Berlin, Allemagne, le 17 juin 2026, 18 h 30 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie en phase clinique spécialisée dans le [...]
Minutes of the TME Pharma Annual General Meeting
17/06/2026
Minutes of the TME Pharma Annual General Meeting Berlin, Germany, June 17, 2026, 6:30 p.m. CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of [...]
Applied Biologics Announces Completion of Planned Enrollment Activities in the CAMPX Randomized Controlled Trial Evaluating XWRAP®
17/06/2026
SCOTTSDALE, Ariz., June 17, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
Ontario Shores partners with community organizations to bring dementia care training to families
17/06/2026
Whitby, Ontario, June 17, 2026 (GLOBE NEWSWIRE) -- Ontario Shores Centre for Mental Health Sciences (Ontario Shores) announced today that it is partnering with the Alzheimer Society of Durham Region to expand access to [...]
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
17/06/2026
First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment i More than 3 million cases of cUTIs are treated annually in [...]
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
17/06/2026
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2042 THIS POSITIVE DECISION FROM THE USA [...]
Eurobio Scientific: ERRATUM : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
17/06/2026
ERRATUM : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Paris, le 17 juin 2026 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro pour la [...]
Le brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 2042
17/06/2026
COMMUNIQUÉ DE PRESSE LE BREVET D’AB SCIENCE CONCERNANT LE MASITINIB DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RÉSISTANT A ÉTÉ OFFICIELLEMENT DÉLIVRÉ AUX ÉTATS-UNIS AVEC UNE DURÉE DE PROTECTION [...]
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
17/06/2026
100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy Complete [...]
BPGbio Presents Latest Clinical and Translational Findings Supporting BPM31510 in Primary CoQ10 Deficiency at Mito Med 2026
17/06/2026
Presentations highlight clinical outcomes in pediatric PCQD subjects and translational evidence supporting tissue delivery and mitochondrial metabolic correction Data support planned Phase 3 pivotal trial in PCQD [...]
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
17/06/2026
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway [...]
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
17/06/2026
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027 CAMBRIDGE, Mass [...]
Precision Neuroscience™ Wins 2026 Webby Award; Earns Back-to-Back Fast Company World Changing Ideas Honor
17/06/2026
Both recognitions cite the Layer 7 cortical interface and its potential to restore independence for people living with paralysis NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision [...]
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
17/06/2026
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients [...]

Pages